… 01, 2012 10:00 am ET Executives James M . Cornelius - Non-Executive Chairman Sandra ..... Analysts Unknown Analyst Presentation James M . Cornelius Good morning, ladies and gentlemen. I'm Jim Cornelius , the Non-Executive Chairman of …
… in acquisitions. In early 2010, Lamberto Andreotti and Charles Bancroft took over Bristol's top posts, replacing James Cornelius as CEO and Marc Huet as CFO, respectively. While both appointments shouldn't signify a major shift in Bristol's strategy …
… The board of directors consists of 10 members, including Golsby and two holdovers from Bristol-Myers BMY: chairman James Cornelius also serves as Bristol-Myers' chairman, and director Elliott Sigal is Bristol-Myers' chief scientific officer. The …
… confidence in Imclone's rights to pipeline drug candidate 11F8 to follow through with the $70 per share offer. Bristol CEO James Cornelius also intends to ask Imclone shareholders for permission to remove all of the members of Imclone's board and replace them …
… In addition, we don't think Bristol is likely to substantially increase its bid above its initial offer; Bristol CEO James Cornelius has experience being on the right side of a bidding war from his days at Guidant, and we don't think the firm's key …
… announced the appointment of a permanent CEO and a collaboration with Pfizer PFE. Our opinion of the company is unchanged. James Cornelius , who has served as interim CEO for the past eight months, was named permanent CEO. He began serving as interim CEO following …
… Bristol's best-selling drug Plavix was simply one too many mistakes for Bristol's board to stomach. Board member James Cornelius has been named interim CEO, but we expect Bristol's board will undertake a comprehensive search for a permanent replacement …